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OBJECTIVE — In a prospective birth cohort study, we followed infants who had a ﬁrst-
degree relative with type 1 diabetes to investigate the relationship between early growth and
infant feeding and the risk of islet autoimmunity.
RESEARCH DESIGN AND METHODS — Infants with a ﬁrst-degree relative with type
1 diabetes were identiﬁed during their mother’s pregnancy. Dietary intake was recorded pro-
spectively to determine duration of breast-feeding and age at introduction of cow’s milk protein,
cereals, meat, fruit, and vegetables. At 6-month reviews, length (or height) and weight, antibod-
ies to insulin, GAD65, the tyrosine phosphatase-like insulinoma antigen, and tissue transglu-
taminase were measured. Islet autoimmunity was deﬁned as persistent elevation of one or more
isletantibodiesatconsecutive6-monthintervals,includingthemostrecentmeasure,andwasthe
primary outcome measure.
RESULTS — Follow-up of 548 subjects for 5.7  3.2 years identiﬁed 46 children with islet
autoimmunity. Weight z score and BMI z score were continuous predictors of risk of islet
autoimmunity (adjusted hazard ratios 1.43 [95% CI 1.10–1.84], P  0.007, and 1.29 [1.01–
1.67],P0.04,respectively).Theriskofisletautoimmunitywasgreaterinsubjectswithweight
zscore0thaninthosewithweightzscore0overtime(2.61[1.26–5.44],P0.01).Weight
z score and BMI z score at 2 years and change in weight z score between birth and 2 years, but
not dietary intake, also predicted risk of islet autoimmunity.
CONCLUSIONS — Weight gain in early life predicts risk of islet autoimmunity in children
with a ﬁrst-degree relative with type 1 diabetes.
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dentical twin studies and geographic
and temporal variations in incidence
argue for a critical role of the environ-
ment in the development of type 1 dia-
betes (1). Environmental inﬂuences
potentially initiate or accelerate the auto-
immune destruction of the pancreatic is-
lets. The incidence of type 1 diabetes is
increasinginpopulationsworldwidewith
an earlier age of onset described in Euro-
pean and Oceania populations (1). This
rise in childhood incidence parallels in
time the overweight/obesity epidemic in
Western childhood populations.
The accelerator hypothesis proposes
that weight and associated insulin resis-
tance accelerate loss of -cells in both
type 1 and type 2 diabetes, such that they
aredistinguishedonlybytheirrateofpro-
gression (2). Proposed accelerators in-
clude genes, insulin resistance, and
autoimmunity. Although the full implica-
tionsofthishypothesisarebeingdebated,
there is increasing evidence of the impor-
tance of weight, BMI, and relative insulin
insensitivity in the development of type 1
diabetes. Younger age of onset of type 1
diabetes is associated with higher BMI at
diagnosis in large cohorts (3), and in one
study, the association was seen only in
childrenwithlowerfastingC-peptidelev-
els (4). We and others have shown that
surrogate markers of insulin resistance
and BMI predict progression to type 1 di-
abetesinsubjectswithisletautoimmunity
(5,6). These ﬁndings support weight and
relative insulin insensitivity as accelerat-
ing -cell loss after the development of
islet autoimmunity when insulin secre-
tion is falling rather than before. How-
ever, only prospective studies from birth
can resolve this question.
Retrospective case-control studies in
Europe link increased linear growth and
weight gain in childhood, particularly in
the ﬁrst 2 years of life, with later onset of
type1diabetes(7–9).Inonestudy,infant
growth was related to detection of ty-
rosine phosphatase-like insulinoma anti-
gen (insulinoma-associated protein 2
[IA2])antibodiesatdiagnosis(9).Reports
from Scandinavia, Germany, and Colo-
rado in the U.S. and our own data have
provided prospective data from birth
(10–17), but there are no data examining
the effect of weight gain on the develop-
ment of islet autoimmunity or type 1 dia-
betes in birth cohort studies. Diet, in
terms of introduction and intake of cow’s
milk protein, cereals, -3 fatty acids,
fruits, and root vegetables, is a putative
inﬂuenceonthedevelopmentofisletauto-
immunity (12–17).
The Australian Baby Diab Study has
prospectively followed from birth infants
who have a ﬁrst-degree relative with type
1 diabetes and live in Victoria or South
Australia (10,11). We aimed to investi-
gate the relationship between early
growth (weight, length, and height gain)
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opment of islet autoimmunity.
RESEARCH DESIGN AND
METHODS— All subjects were par-
ticipants in the Australian Baby Diab
Study. Probands included mothers, fa-
thers,andsiblingswithtype1diabetes.In
17of548(3.1%)families,therewasmore
than one ﬁrst-degree relative with type
1 diabetes. Subjects were identiﬁed
through local diabetes associations and
clinics, recruited during their pregnancy,
and followed prospectively from birth
with 6-month reviews. All infants had
normal growth and development apart
from four with congenital anomalies who
were excluded from the study. At each
6-month review, length (if 2 years of
age) or height and weight were measured
in the majority of infants using a clinic
Harpenden stadiometer (Holtain, Cry-
mych, Wales) to the nearest 0.1 cm and
balance scales. Measurements were con-
vertedtoweightzscore,heightzscore,or
length z score to account for normal
growth in childhood. After 2 years of age,
BMI (weight in kilograms divided by the
square of height in meters) and BMI z
score were also calculated.
Dietary intake was documented in a
home diary by parents and recorded dur-
ing face-to-face interviews at 6-month
reviews. No systematic infant feeding ad-
vice was given. Six-month venous speci-
mens were collected for measurement of
insulin autoantibodies and antibodies to
GAD65, IA2, and tissue transglutami-
nase. HLA typing was performed on cord
blood.
The study was approved by the
Women’s and Children’s Hospital’s Hu-
man Research and Ethics Committee and
the Royal Melbourne Hospital’s Human
Research and Ethics Committee. Parents
gave written informed consent for their
child to enter the study.
Dietary records
The following were recorded by the
child’s parent or guardian in the home
diary: 1) duration of exclusive breast-
feeding, 2) total duration of breast-
feeding, 3) dairy products consumed by
the mother while breast-feeding, 4) age at
introduction of cow’s milk–based infant
formulae, 5) commercial brand of infant
formulae, 6) age at introduction of cow’s
milk as cow’s milk or other dairy prod-
ucts, 7) age at introduction of nongluten
(rice)-containing cereals, 8) age at intro-
duction of gluten-containing (wheat, bar-
ley, rye, and oats) cereals, and 9) age at
introduction of meat, meat products,
fruit, and vegetable solids.
Autoantibodies
Insulin autoantibodies (IAAs) were as-
sayed by a modiﬁcation of the ﬂuid phase
radiobinding assay as described previ-
ously (10,11). The interassay coefﬁcient
of variation (CV) was 16%. GAD and IA2
antibodies were assayed by immuno-
precipitation of [
35S]methionine-labeled
recombinant human proteins as de-
scribed previously (10,11). The inter-
assay CVs for GAD and IA2 were 12 and
19%, respectively. In the 2005 Diabetes
Autoantibody Standardization Program,
workshop sensitivity and speciﬁcity for
theGADantibodyassaywerescoredas86
and 99%, for the IA2 antibody assay 64
and100%,andfortheIAAantibodyassay
22 and 99%, respectively.
Elevation of islet antibodies was de-
ﬁnedasIAAs5.5%,GADantibodies5
units, or IA2 antibodies 3 units. Islet
autoimmunity was deﬁned as persistent
elevation of one or more islet antibodies





IgA kit (code 708760; INOVA Diagnos-
tics, San Diego, CA). Elevation of tissue
transglutaminase antibodies was deﬁned
as 20 units. The interassay CV for the
negative control (3.6 units/ml) was 12.2%,
andtheinterassayCVforthepositivecon-
trol (105.0 units/ml) was 3.3%.
HLA typing
HLA-A and -B (class I) typing was per-
formed by a standard serologically based
microlymphocytotoxicity assay using T
lymphocytes separated from whole blood
using magnetic beads coated with a T-cell
monoclonal antibody. Class II (DRB1)
typing was performed by hybridization of
PCR-ampliﬁed DRB1 exon 2 DNA with
sequence-speciﬁc oligonucleotide probes
accordingtothe11thInternationalHisto-
compatibility Workshop protocol but
with minor modiﬁcations as described
previously (10,11).
Statistical analysis
Time-to-event analyses were used to ex-
plore the effect of weight and diet on the
risk of islet autoimmunity. Parametric
survivalmodelswereusedtocomparethe
age when islet autoimmunity developed
across categories of exposure to the risk
factors of interest. Time to development
ofisletautoimmunitywasassumedtofol-
low a Gompertz distribution. Unadjusted
and adjusted hazard ratios (HRs) were
calculated by parametric survival models,
which accounted for inconsistent length
of follow-up and right-censored data. A
total of 4,598 weight and length or height
measurements were obtained from 548
subjects. These were converted into
weight z score and BMI z score (from 2
years) by reference to the Centers for Dis-
ease Control and Prevention 2000 stan-
dardized reference growth charts (http://
www.cdc.gov/nchs/). Subjects with
missing data for HLA or dietary variables
5% were allocated to the “unknown”
category, which was included in the anal-
ysis (Tables 1–3). The maximum number
of subjects with missing data for a risk
factor was 30% (Table 1), and these sub-
jects included those who had fewer miss-
ing data for other variables. Of the 548
subjects, 44 (8.0%) subjects had a miss-
ing weight at 2 or 4 years, and 18 of 548
(3%) subjects had a missing birth weight;
these subjects were excluded from analy-




tered into their respective parametric
survival model as time-dependent covari-
ates. Adjusted HRs were used to analyze
the development of islet autoimmunity
with weight z score and BMI z score over
time while controlling for HLA type and
with weight z score and BMI z score at 2
and 4 years while controlling for birth
weight z score and HLA type. For each
variable, subjects with incomplete data
didnotdiffersigniﬁcantlyfromsubjects
with complete data with respect to
mean follow-up time and frequency of
islet autoimmunity. Statistical analyses
were performed in Stata version 9 and
SPSS 14.0. The level of signiﬁcance was
0.05.
RESULTS— Of the 548 subjects, 46
(8.4%; 21 male) who were followed from
birth for a mean  SD of 5.7  3.2 years
developed islet autoimmunity as deﬁned
above, of whom 12 progressed to type 1
diabetes at 4.2  2.1 years. Median age of
onset of islet autoimmunity was 1.7 years
(range 0.2–8.6 years). Characteristics of
the study cohort are shown in Table 1.
The most common raised islet antibody
wasIAAin39of46(85%)subjects.Inthe
islet autoimmunity group, 14 subjects
(30%) were positive for one islet anti-
Couper and Associates
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and14(30%)forallthreeisletantibodies.
In 2 of 20 subjects with transplacental
transfer of an islet antibody from their
mother with type 1 diabetes, this result
was not transient, and they were catego-
rizedashavingisletautoimmunity.Twenty-
four of 421 (5.7%) subjects (12 male)
developed raised tissue transglutaminase
antibodies at 6.4  2.6 years.
Weight z score
Weight z score over time was a continu-
ous predictor of risk of islet autoimmu-
nity (Table 2) and remained a continuous
predictor of risk of islet autoimmunity af-
ter controlling for HLA type (adjusted HR
1.43 [95% CI 1.10–1.84] per unit in-
crease in z, P  0.007). Weight z score
and BMI z score at 2 and 4 years were
normally distributed. Weight z score at 2
years and change in weight z score be-
tween birth and 2 years predicted risk of
islet autoimmunity (Tables 2 and 3).
Weight z score at 4 years and change in
weight z score between birth and 4 years
showed a trend toward predicting risk of
islet autoimmunity (Table 2). Birth
weight z score was associated with weight
z score at 2 years (r  0.27, P  0.001)
and4years(r0.28,P0.001).Weight
z score at 2 years remained a signiﬁcant
predictor of islet autoimmunity after con-
trolling for birth weight z score and HLA
type (Table 3). When weight z score over
time was recorded in four categories (1
or less, more than 1 to 0 or less, 0t o
1, and 1), there was a signiﬁcant dif-
ference in the risk of islet autoimmunity









HLA type (adjusted HR 1 for weight z
score 0; HR 2.61 [95% CI 1.26–5.44]
for weight z score 0,P  0.01). Length
z score or height z score did not predict
risk of islet autoimmunity development
over time, and length z score at 2 years or
height z score at 4 years did not either.
BMI z score
BMI z score over time was a continuous
predictor of risk of islet autoimmunity
(Table2)andremainedacontinuouspre-
dictor of risk of islet autoimmunity after
controlling for HLA type (adjusted HR
1.29 [95% CI 1.01–1.67] per unit in-
crease in z, P  0.04). BMI z score pre-
dicted risk of islet autoimmunity at 2
yearsbutnot4years(Table2).WhenBMI
zscoreovertimewasdichotomizedas0
or 0, there was a borderline signiﬁcant
difference in risk of islet autoimmunity
between the two categories [
2(1)  2.7,
P  0.09] (Table 2). There was no signif-
icant difference in risk of islet autoim-
munity between the two BMI z score
categories after controlling for HLA type
(adjusted HR 1 for BMI z score 0, HR
1.69 [95% CI 0.90–3.30] for BMI z score
0, P  0.12). Weight z score or BMI z
score did not relate to the number of islet







Age in years* 2.2  1.7 5.8  3.2
Caucasian 45 491 0.92
Male sex 21 (46) 275 (54) 0.28
HLA DR-3,4 16 (35) 50 (10) 0.001
HLA DR-3x or HLA DR-4x 20 (43) 266 (53)
Other 5 (11) 65 (13)
Unknown 5 (11) 118 (24)
Birth weight z score 0.28  1.28 0.25  1.18 0.86
Gestational age 38.6  2.2 38.1  2.7 0.25
Weight z score
At 2 years 0.79  1.12 0.34  1.17 0.02
At 4 years 0.77  0.91 0.46  1.10 0.08
BMI z score
At 2 years 0.90  0.90 0.39  1.21 0.02
At 4 years 0.76  0.96 0.44  1.18 0.11
Duration of exclusive breast-feeding
0 months 8 (17) 98 (19) 0.98
0–3 months 10 (22) 99 (20)
3 months 16 (35) 176 (35)
Unknown 12 (26) 129 (26)
Total duration of breast-feeding
0 months 4 (9) 49 (10) 0.74
0–3 months 7 (15) 100 (20)
3 months 23 (50) 252 (50)
Unknown 12 (26) 101 (20)
Age of introduction of cow’s milk protein†
0–3 months 15 (33) 182 (36) 0.21
3 months 28 (61) 248 (49)
Unknown 3 (7) 72 (14)
Age of introduction of nongluten cereal
0–4 months 18 (39) 176 (35) 0.80
4 months 14 (31) 174 (34)
Unknown 14 (30) 152 (30)
Age of introduction of gluten
0–4 months 5 (11) 59 (12) 0.86
4 months 30 (66) 340 (68)
Unknown 11 (24) 103 (21)
Breast-fed at introduction of cereals
Yes 21 (46) 228 (45) 0.83
No 13 (28) 160 (32)
Unknown 12 (26) 114 (23)
Breast-fed at introduction of cow’s milk
Yes 12 (26) 134 (26) 0.78
No 21 (46) 249 (50)
Unknown 13 (28) 119 (24)
Data are means  SD or n (%). *For islet autoimmune, age at visit when ﬁrst tested positive for autoanti-
bodies. For not islet autoimmune, age at last visit. †Cow’s milk protein introduced as infant formulae, dairy
products, or cow’s milk.
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autoimmunity.
Dietary intake
A food diary was completed for 505 of
548 (92.1%) subjects. Duration of breast-
feeding and introduction of cow’s milk
protein and cereals are shown in Table 1.
No subject who developed islet autoim-
munity received cereals before 3 months
of age including 16 subjects exposed to
gluten; therefore, introduction of cereal
was categorized before and after 4
months. Risk of development of islet au-
toimmunitydidnotrelatetothetimingof
introduction of gluten-containing or
gluten-free cereals (rice cereals), cow’s
milk–based infant formulae (containing
intact cow’s milk protein), cow’s milk,
dairy products (Table 2), soy milk, meat,
fruit, or vegetables. Risk of development
ofisletautoimmunitydidnotrelatetodu-
ration of exclusive breast-feeding or total
duration of breast-feeding (Table 2). Risk
ofdevelopmentofisletautoimmunitywas
not altered by whether a subject was
breast-fed at the time of introduction of
cereals or cow’s milk (Table 2).
Pregnancy and birth
Parity, sex of the child, gestational age,
and birth weight z score did not relate to
risk of islet autoimmunity (Table 2).
HLA genotypes
HLA genotypes were categorized as HLA-
DR-3,4; HLA-DR-4,x; HLA-DR-3,x;
HLA-DR-2,x; and HLA-DR-x,x. There
was no difference between the frequency
of HLA-DR-3,4; HLA-DR-4,x; and HLA-
DR-3,xbetweenthosewithweightzscore
0 (81%) and those with weight z score
0 (84%) in the islet autoimmunity
group (P  0.7). HLA-DR-3,x was
present in 13 of 21 subjects who devel-
oped transglutaminase antibodies.
CONCLUSIONS — This prospective
study from birth shows for the ﬁrst time
that early weight gain in childhood inde-
pendently predicts the risk of early islet
autoimmunity in children with an in-
creased genetic risk of type 1 diabetes.
The effect of weight gain both as weight z
score and BMI z score was seen continu-
ously over the 6 years of follow-up.
Weight gain during the ﬁrst 2 years of life
was more predictive than weight gain
during the ﬁrst 4 years. This ﬁnding was
expected because islet autoimmunity de-
velopedonaverageby2yearsandempha-
sizes the contribution of weight gain on
Table 2—Parametric survival model on risk of islet autoimmunity
Risk factor n Unadjusted HR (95% CI) P
Weight z score over time 1.44 (1.12–1.87) 0.004
Weight z score
0 1,932 1.0 0.006
0 2,664 2.77 (1.33–5.75)
2 years 1.38 (1.05–1.83) 0.02
4 years 1.29 (0.96–1.73) 0.08
Change in weight z score
Between birth and 2 years 1.28 (1.04–1.59) 0.02
Between birth and 4 years 1.23 (0.98–1.53) 0.07
BMI z score over time 1.31 (1.02–1.68) 0.03
BMI z score
0 1,902 1.0 0.09
0 2,431 1.81 (0.93–3.52)
2 years 1.42 (1.06–1.89) 0.02
4 years 1.27 (0.95–1.72) 0.11
Age of introduction of gluten
4 months 0.90 (0.35–2.33) 0.62
4 months 1
Unknown 1.39 (0.70–2.78)
Age of introduction of nongluten cereals
4 months 1.21 (0.60–2.42) 0.70
4 months 1
Unknown 1.33 (0.63–2.79)
Duration of exclusive breast-feeding
0 months 0.95 (0.40–2.21) 0.94
0–3 months 1.12 (0.51–2.46)
3 months 1
Unknown 1.21 (0.60–2.56)
Total duration of breast-feeding
0 months 0 0.93 (0.32–2.70) 0.49
0–3 months 0.82 (0.35–1.91)
3 months 1
Unknown 1.57 (0.78–3.15)
Age of introduction of cow’s milk protein*
0–3 months 0.78 (0.42–1.46) 0.47
3 months 1
Unknown 0.28 (0.52–1.71)
Breast fed at introduction of cow’s milk*
Yes 1.01 (0.50–2.05) 0.49
No 1
Unknown 1.49 (075–2.97)
Breast fed at introduction of cereals
Yes 1.08 (0.54–2.15) 0.61
No 1
Unknown 1.45 (0.66–3.18)




Birth weight z score 1.04 (0.82–1.33) 0.74
Gestational age 1.10 (0.95–1.28) 0.20
HLA-DR
3, 4 1 0.001
3x or 4x 0.27 (0.14–0.51)
Unknown 0.21 (0.08–0.57)
*Cow’s milk protein introduced as infant formulae, dairy products, or cow’s milk.
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Similarly, weight z score was expected
to be a stronger predictor than BMI z
score, as BMI is not calculated until 2
years of age.
Rapid weight gain, as occurs in early
life, may increase -cell destruction if
metabolically active -cells are more vul-
nerable to damage than resting -cells.
Increased insulin secretion and high glu-
cose upregulate GAD and Fas to Fas li-
gand, respectively, in -cells in vitro
(18,19). Metabolically active -cells may
therefore be destroyed by autoimmune
(18) and nonautoimmune mechanisms
(19); this destruction could occur inde-
pendentlyortogetheraccordingtothein-
dividual’s genetic makeup.
We found no relationship between
infant feeding and risk of islet autoimmu-
nity, including detailed analysis of breast-
feeding duration (total and exclusive),
introduction of cow’s milk protein (in
infant formulae and milk solids), and
introduction of gluten-free and gluten-
containing cereals. There is an interaction
between diet and weight gain in early
childhood in the normal population.
Formula-fed infants have accelerated
weightgainfrom3monthsincomparison
with breast-fed infants and an increased
risk of overweight during childhood
(20,21). Infant feeding practices them-
selves are interrelated in most popula-
tions in that breast-fed infants receive
cereals in their diet later than bottle-fed
infants. However, it is not possible to
reconcile variable ﬁndings of the effect
of infant diet on the development of is-
let autoimmunity (11–17), including
reported harmful effects of early intro-
duction of cow’s milk or cereals (12–
14), by an overriding risk of weight
gain. To our knowledge no previous
prospective birth cohort study of the
development of islet autoimmunity has
analyzed the contribution of weight and
heightdata,inadditiontoinfantdiet,to
risk of islet autoimmunity.
A limitation of this study is that the
outcome measure was development of is-
let autoimmunity rather than type 1 dia-
betes. However, a number of studies have
shown that persistent islet autoimmunity
confersahighriskoflaterdevelopmentof
type 1 diabetes in ﬁrst-degree relatives of
individuals with type 1 diabetes (22). In
addition, there were signiﬁcant missing
datainprospectivedietrecordsforbreast-
feeding and introduction of cereals, re-
stricting the power of these risk analyses
such that an effect could have been
missed. These limitations are common to
other birth cohort studies also and, in the
case of prospective diet data, similar rates
of data collection are described (12). We
had robust power to relate weight and
BMI to risk of islet autoimmunity.
Prior observations support weight
gain driving -cell loss after the develop-
ment of islet autoimmunity as children
progress to type 1 diabetes (4–6). We
have extended this argument to show, in
the ﬁrst birth cohort study, that being
above average in weight in early life in-
creases the risk of islet autoimmunity in
childrenwithincreasedgeneticrisk.Over
the next decade, the cohort can be fol-
lowed to determine whether weight gain
in the ﬁrst years of life also predicts speed
of progression to type 1 diabetes. Our
ﬁndings have major implications for in-
terventionstocurbtheepidemicoftype1
diabetes in early childhood and to target
nutrition and weight gain in the ﬁrst and
second years of life.
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